Bokf Na Has $6.47 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Bokf Na decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,930 shares of the medical device company’s stock after selling 460 shares during the quarter. Bokf Na’s holdings in DexCom were worth $6,474,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of DXCM. Capital World Investors boosted its stake in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares in the last quarter. Norges Bank bought a new position in DexCom in the 4th quarter valued at $540,178,000. Artisan Partners Limited Partnership raised its position in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors raised its position in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in DexCom in the 4th quarter valued at $231,773,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 40.7 %

NASDAQ:DXCM traded down $43.85 on Friday, reaching $64.00. The company’s stock had a trading volume of 53,914,127 shares, compared to its average volume of 2,657,874. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm has a market cap of $25.45 billion, a PE ratio of 41.29, a PEG ratio of 1.57 and a beta of 1.16. The business’s 50-day moving average price is $115.28 and its two-hundred day moving average price is $123.79.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 32.27% and a net margin of 16.95%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. The company’s revenue was up 15.3% on a year-over-year basis. Equities research analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Morgan Stanley dropped their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday. Stifel Nicolaus dropped their target price on DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a research report on Friday. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Finally, Royal Bank of Canada dropped their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $113.06.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at $8,611,765. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael Jon Brown sold 629 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at $8,611,765. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,112 shares of company stock valued at $480,861. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.